DB18187InvestigationalProtein Based Therapies
Nemvaleukin alfa: Overview.
- Mechanism
- Curator reviewed
Pharmacologically active on Interleukin-2 receptor
- Also known as
- 75-133-interleukin 2 (125-serine) (human) fusion protein with peptide linker (gg) fusion protein with 4-74-interleukin 2 (human) fusion protein with peptide linker (gsgggs) fusion protein with 1-165-interleukin 2 receptor .alpha.-chain (human) · 75-133-Interleukin 2 [125-serine] (human) fusion protein with peptide linker (GG) fusion protein with 4-74-interleukin 2 (human) fusion protein with peptide linker (GSGGGS) fusion protein with 1-165-interleukin 2 receptor α-chain (human) · Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha · human interleukin 2 fragment (1-59), variant (Cys125>Ser51), fused via peptidyl linker (60GG61) to human interleukin 2 fragment (62-132), fused via peptidyl linker (133GSGGGS138) to human interleukin 2 receptor α-chain fragment (139-303), produced in Ch
- Code names
- ALKS-4230 · RDB-1450
Resolves to
Compound
What you can answer from here — as of July 08, 2026
Which companies are running trials of Nemvaleukin alfa, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account